U.S. Markets close in 1 hr 53 mins

Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (TSLA), Nordson Corporation (NDSN), Paycom Software, Inc. (PAYC), PDL BioPharma, Inc. (PDLI), Corcept Therapeutics Incorporated (CORT), and Willis Towers Watson Public Limited Company (WLTW), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

TSLA DOWNLOAD: http://MarketSourceResearch.com/register/?so=TSLA
NDSN DOWNLOAD: http://MarketSourceResearch.com/register/?so=NDSN
PAYC DOWNLOAD: http://MarketSourceResearch.com/register/?so=PAYC
PDLI DOWNLOAD: http://MarketSourceResearch.com/register/?so=PDLI
CORT DOWNLOAD: http://MarketSourceResearch.com/register/?so=CORT
WLTW DOWNLOAD: http://MarketSourceResearch.com/register/?so=WLTW

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Tesla, Inc. (TSLA), Nordson Corporation (NDSN), Paycom Software, Inc. (PAYC), PDL BioPharma, Inc. (PDLI), Corcept Therapeutics Incorporated (CORT), and Willis Towers Watson Public Limited Company (WLTW) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

TESLA, INC. (TSLA) REPORT OVERVIEW

Tesla's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Tesla reported revenue of $6,824.41MM vs $2,984.68MM (up 128.65%) and analysts estimated basic earnings per share $1.82 vs -$3.70. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Tesla reported revenue of $11,758.75MM vs $7,000.13MM (up 67.98%) and analysts estimated basic earnings per share -$11.83 vs -$4.68. Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$3.84. The estimated EPS forecast for the next fiscal year is $2.80 and is expected to report on February 6th, 2019.

To read the full Tesla, Inc. (TSLA) report, download it here: http://MarketSourceResearch.com/register/?so=TSLA

-----------------------------------------

NORDSON CORPORATION (NDSN) REPORT OVERVIEW

Nordson's Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, Nordson reported revenue of $581.24MM vs $589.44MM (down 1.39%) and analysts estimated basic earnings per share $1.63 vs $1.76 (down 7.39%). For the twelve months ended October 31st, 2017 vs October 31st, 2016, Nordson reported revenue of $2,066.98MM vs $1,808.99MM (up 14.26%) and analysts estimated basic earnings per share $5.14 vs $4.76 (up 7.98%). Analysts expect earnings to be released on December 12th, 2018. The report will be for the fiscal period ending October 31st, 2018. Reported EPS for the same quarter last year was $1.38. The estimated EPS forecast for the next fiscal year is $6.64 and is expected to report on December 12th, 2018.

To read the full Nordson Corporation (NDSN) report, download it here: http://MarketSourceResearch.com/register/?so=NDSN

-----------------------------------------

PAYCOM SOFTWARE, INC. (PAYC) REPORT OVERVIEW

Paycom Software's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Paycom Software reported revenue of $133.29MM vs $101.29MM (up 31.59%) and analysts estimated basic earnings per share $0.50 vs $0.36 (up 38.89%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Paycom Software reported revenue of $433.05MM vs $329.14MM (up 31.57%) and analysts estimated basic earnings per share $1.15 vs $0.76 (up 51.32%). Analysts expect earnings to be released on February 5th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.24. The estimated EPS forecast for the next fiscal year is $2.76 and is expected to report on February 5th, 2019.

To read the full Paycom Software, Inc. (PAYC) report, download it here: http://MarketSourceResearch.com/register/?so=PAYC

-----------------------------------------

PDL BIOPHARMA, INC. (PDLI) REPORT OVERVIEW

PDL BioPharma's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, PDL BioPharma reported revenue of $67.90MM vs $62.75MM (up 8.21%) and basic earnings per share $0.18 vs $0.14 (up 28.57%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, PDL BioPharma reported revenue of $320.06MM vs $244.30MM (up 31.01%) and analysts estimated basic earnings per share $0.71 vs $0.39 (up 82.05%). Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The estimated EPS forecast for the next fiscal year is $0.13 and is expected to report on March 14th, 2019.

To read the full PDL BioPharma, Inc. (PDLI) report, download it here: http://MarketSourceResearch.com/register/?so=PDLI

-----------------------------------------

CORCEPT THERAPEUTICS INCORPORATED (CORT) REPORT OVERVIEW

Corcept Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Corcept Therapeutics reported revenue of $64.45MM vs $42.76MM (up 50.70%) and analysts estimated basic earnings per share $0.15 vs $0.12 (up 25.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Corcept Therapeutics reported revenue of $159.20MM vs $81.32MM (up 95.77%) and analysts estimated basic earnings per share $1.14 vs $0.07 (up 1,528.57%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.17. The estimated EPS forecast for the next fiscal year is $0.99 and is expected to report on February 28th, 2019.

To read the full Corcept Therapeutics Incorporated (CORT) report, download it here: http://MarketSourceResearch.com/register/?so=CORT

-----------------------------------------

WILLIS TOWERS WATSON PUBLIC LIMITED COMPANY (WLTW) REPORT OVERVIEW

Willis Towers Watson Public's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Willis Towers Watson Public reported revenue of $1,859.00MM vs $1,852.00MM (up 0.38%) and analysts estimated basic earnings per share $0.34 vs -$0.40. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Willis Towers Watson Public reported revenue of $8,202.00MM vs $7,887.00MM (up 3.99%) and analysts estimated basic earnings per share $4.21 vs $3.07 (up 37.13%). Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $2.21. The estimated EPS forecast for the next fiscal year is $11.02 and is expected to report on February 14th, 2019.

To read the full Willis Towers Watson Public Limited Company (WLTW) report, download it here: http://MarketSourceResearch.com/register/?so=WLTW

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.